Chimerix Inc

$6.38 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Chimerix Inc

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.

Stock Analysis

last close $6.38
1-mo return 2.9%
3-mo return -22.2%
avg daily vol. 866.25T
52-week high 11.57
52-week low 2.43
market cap. $548M
forward pe -
annual div. -
roe -130.3%
ltg forecast -
dividend yield -
annual rev. $5M
inst own. 57.5%
baraka

Subscribe now for daily local and international financial news

Subscribe